Welcome to our dedicated page for Abbvie news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on Abbvie stock.
AbbVie Inc. reports pharmaceutical developments across immunology, neuroscience, oncology and Allergan Aesthetics. Recurring updates include financial results by product portfolio, clinical and real-world data for therapies such as SKYRIZI and RINVOQ, FDA regulatory submissions and response letters, and medical-conference presentations in inflammatory bowel disease and other immune-mediated conditions.
Company news also covers pipeline spending, acquired in-process research and development, manufacturing capacity for medicines in core therapeutic areas, and investor conference appearances. AbbVie’s product references commonly include SKYRIZI, RINVOQ, Botox Therapeutic, Vraylar, Ubrelvy, Qulipta, Venclexta, Imbruvica and Elahere.
Allergan Aesthetics (NYSE: ABBV) received a positive CHMP opinion for Boey (trenibotulinumtoxinE) to temporarily improve moderate to severe glabellar lines in adults in 30 EU/EEA markets. Recommendations follow two Phase 3 trials meeting all endpoints, showing onset from 8 hours and 2–3 weeks’ efficacy, with adverse events similar to placebo.
AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on May 13, 2026, with management appearing in a fireside chat at 1:20 p.m. Central Time. A live audio webcast will stream on AbbVie’s Investor Relations website, with an archive available later that day.
AbbVie (NYSE: ABBV) reported 18 abstracts at DDW 2026 highlighting real-world and clinical long-term data for risankizumab and upadacitinib in Crohn's disease and ulcerative colitis. Results include sustained symptom and endoscopic improvements, reduced corticosteroid use, quality-of-life gains, lower switch rates, and lower hospitalization odds.
NImmune Biopharma (NYSE:ABBV) presented Phase 1 and preclinical data at Digestive Disease Week 2026 showing that oral, once-daily NIM-1324 met primary and secondary endpoints, engaged the LANCL2 target, showed improved PK, and had a favorable safety profile with no dose-limiting toxicities.
The program advances a LANCL2 immunometabolic mechanism for ulcerative colitis and Crohn’s disease and supports a well-powered Phase 2 testing 125, 250, and 1000 mg doses versus placebo.
Allergan Aesthetics (NYSE: ABBV) announced a charitable initiative for Skin Cancer Awareness Month on April 30, 2026. Throughout May, Allē will donate $10 for every new member who joins via referral, capped at $100,000. New referred members get $50 off their first treatment; referrers receive $10 off their next treatment. Referrals must be made through the Allē app and qualifying treatment and purchase must occur within 60 days of registration. Terms limit five referral offers per member per calendar year.
AbbVie (NYSE:ABBV) reported Q1 2026 net revenues of $15.002B, up 12.4% reported (10.3% operational). GAAP diluted EPS was $0.39; adjusted diluted EPS was $2.65, which includes an unfavorable $0.41 per-share impact from acquired IPR&D and milestones. AbbVie raised 2026 adjusted EPS guidance to $14.08–$14.28 (includes the $0.41 impact year-to-date).
Key portfolio highlights: Skyrizi $4.483B, Rinvoq $2.119B, Humira $688M; neuroscience $2.875B; oncology $1.631B; aesthetics $1.186B. Major items include FDA approval for Venclexta+acalabrutinib in frontline CLL, FDA CRL for trenibotE manufacturing, regulatory submissions for Skyrizi CD and Rinvoq alopecia areata, and multi-site manufacturing investments totaling $1.78B.
AbbVie (NYSE: ABBV) submitted an FDA application for upadacitinib (RINVOQ) 15 mg and 30 mg once daily for adults and adolescents with severe alopecia areata, based on Phase 3 UP-AA data.
In two replicate trials (N=1,399), the primary endpoint SALT ≤ 20 at week 24 was met for both doses; response rates improved through week 52. Safety through week 52 was described as consistent with earlier results. Use in AA is not approved and remains under regulatory review.
AbbVie (NYSE: ABBV) submitted an application to the FDA on April 27, 2026, seeking approval for SKYRIZI (risankizumab-rzaa) as a subcutaneous (SC) induction treatment for adults with moderately to severely active Crohn's disease.
The filing is supported by positive Phase 3 AFFIRM study data and would give patients an option between SC induction or the existing IV induction, continuing SC maintenance every eight weeks if approved.
AbbVie (NYSE: ABBV) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration on April 23, 2026 for its Biologics License Application for trenibotulinumtoxinE (TrenibotE).
The FDA requested additional information about manufacturing processes; the CRL did not identify safety or efficacy concerns and did not request additional clinical studies. AbbVie expects to submit a response in the coming months and says international regulatory reviews are progressing.
AbbVie (NYSE: ABBV) will invest $1.4 billion to build a new 185-acre pharmaceutical manufacturing campus in Durham, North Carolina, supporting production of immunology, neuroscience and oncology medicines.
Construction begins in 2026 with completion expected by end of 2028, creating 734 full-time jobs and more than 2,000 construction jobs, and forming part of AbbVie's $100 billion U.S. R&D and capital commitment.